Sage Therapeutics Inc. Stock
Price
Target price
€11.53
€11.53
0.040%
0.005
0.040%
€26.71
08.05.24 / Tradegate
WKN: A117WF / Symbol: SAGE / Name: SAGE / Stock / Biotechnology & Medical Research / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Sage Therapeutics Inc. Stock
There is nearly no change for the Sage Therapeutics Inc. stock today. Compared to yesterday it only changed by €0.005.
Currently there is a rather positive sentiment for Sage Therapeutics Inc. with 5 Buy predictions and 3 Sell predictions.
With a target price of 26 € there is potential for a 125.5% increase which would mean more than doubling the current price of 11.53 € for Sage Therapeutics Inc..
So far the community has only identified positive things for Sage Therapeutics Inc. stock. The most positive votes were given for criterium "Valuation (undervalued/overvalued)".
Pros and Cons of Sage Therapeutics Inc. in the next few years
Pros
?
M***** P*******
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
Cons
?
S********** s********
?
G***** c******* t* c**********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Sage Therapeutics Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Sage Therapeutics Inc. | 0.040% | -11.648% | -24.641% | -75.363% | -42.350% | -80.719% | - |
| Ironwood Pharmaceuticals | 0.670% | 2.759% | 2.055% | -22.798% | -26.961% | -18.132% | - |
| Novocure Ltd | 0.030% | 30.065% | 14.280% | -76.332% | 4.553% | -90.566% | - |
| Iovance Biotherapeutics Inc. | -0.920% | 12.908% | 3.573% | 93.857% | 59.644% | -46.822% | - |
Comments
Sage Therapeutics, Inc. (NASDAQ: SAGE) had its price target lowered by analysts at JPMorgan Chase & Co. from $29.00 to $28.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for SAGE provided by MarketBeat
Sage Therapeutics, Inc. (NASDAQ: SAGE) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Show more
Ratings data for SAGE provided by MarketBeat
Sage Therapeutics, Inc. (NASDAQ: SAGE) had its price target raised by analysts at JPMorgan Chase & Co. from $24.00 to $29.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for SAGE provided by MarketBeat
News
5 Biotech stocks tapping into unmet mental health treatment needs
Anyone who has dealt with a mental illness or has a loved one who struggles with a mental illness knows how devastating these diseases are. However, a growing number of biotechnology companies are
